Breaking News Instant updates and real-time market news.

CVS

CVS Health

$69.92

0.39 (0.56%)

07:38
02/20/19
02/20
07:38
02/20/19
07:38

CVS Health sees Q1 adjusted EPS $1.49-$1.53, consensus $1.67

Sees Q1 consolidated revenue $59.61B-$60.53B, consensus $59.79B. Sees Q1 adjusted operating income $3.39B-$3.45B. Seasonality of its expected results this year will closely resemble that of its reported results last year. Says year-over-year growth of consolidated adjusted operating income will be highest through the first three quarters as it wraps the addition of Aetna. In Retail/LTC and PBM, CVS sees its greatest level of year-over-year deterioration in Q1, with adjusted operating income growth in those segments improving moving through the year. In HCB, adjusted operating income is expected to be greatest in Q1 and lowest in Q4.

  • 20

    Feb

  • 22

    Feb

  • 27

    Feb

CVS CVS Health
$69.92

0.39 (0.56%)

01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.
01/28/19
CLVD
01/28/19
NO CHANGE
CLVD
CVS Health likely lost Coretrust contrac, says Cleveland Research
Cleveland Research said it is likely CVS Health lost the Coretrst contract to OptumRx, on top of the loss of BCBS of South Carolina to OptumRx.
01/31/19
MSCO
01/31/19
NO CHANGE
Target $391
MSCO
Overweight
Anthem price target raised to $391 from $372 at Morgan Stanley
Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating.
02/07/19
MSCO
02/07/19
NO CHANGE
Target $100
MSCO
Overweight
CVS shares could rise 4%-9% on 'good enough' guidance, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser noted that CVS Health will provide guidance on February 20 for the first time since completing the Aetna transaction and he puts 60% odds on initial FY19 EPS guidance of $7.00-$7.30. While such an outlook would be below the current consensus of $7.44, bears are concerned guidance could be below $7 and such an outlook would be seen as "good enough" to drive the stock up 4%-9%, Goldwasser tells investors. If initial 2019 EPS guidance is below $7.00, which is a scenario he gives a 30% probability, the stock could be down 11%. If the initial 2019 EPS guidance range has a midpoint above $7.40, which Goldwasser assigns only 10% odds of happening, the stock could be up 10%, the analyst said. He keeps an Overweight rating and $100 price target on CVS shares ahead of the company's December quarter earnings report.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$121.52

0.795 (0.66%)

13:25
09/23/19
09/23
13:25
09/23/19
13:25
Options
Spotify call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

AMD

AMD

$30.62

0.58 (1.93%)

13:24
09/23/19
09/23
13:24
09/23/19
13:24
Hot Stocks
AMD up 2% to $30.64 in afternoon trading »

At time of writing, AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/23/19
09/23
13:17
09/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/23/19
09/23
13:16
09/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/23/19
09/23
13:15
09/23/19
13:15
General news
Fed's Bullard said the Committee might opt to ease again »

Fed's Bullard said…

NVO

Novo Nordisk

$53.06

0.11 (0.21%)

13:05
09/23/19
09/23
13:05
09/23/19
13:05
Options
Novo Nordisk call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

IPHI

Inphi

$60.80

-2.69 (-4.24%)

, AMZN

Amazon.com

$1,789.48

-4.16 (-0.23%)

12:59
09/23/19
09/23
12:59
09/23/19
12:59
Recommendations
Inphi drops after Northland sees 'large cut' to Amazon 400G rollout plans »

Northland analyst Tim…

IPHI

Inphi

$60.80

-2.69 (-4.24%)

AMZN

Amazon.com

$1,789.48

-4.16 (-0.23%)

CSCO

Cisco

$49.59

(0.00%)

ACIA

Acacia Communications

$64.58

-0.04 (-0.06%)

LITE

Lumentum

$57.55

-1.28 (-2.18%)

NPTN

NeoPhotonics

$6.24

-0.03 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 26

    Sep

  • 10

    Oct

  • 27

    Oct

  • 13

    Nov

HUYA

Huya

$27.43

-0.47 (-1.68%)

12:55
09/23/19
09/23
12:55
09/23/19
12:55
Options
HUYA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLY

Annaly Capital

$9.02

0.06 (0.67%)

12:45
09/23/19
09/23
12:45
09/23/19
12:45
Options
Annaly Capital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:45
09/23/19
09/23
12:45
09/23/19
12:45
Hot Stocks
Breaking Hot Stocks news story on Trio-Tech »

Trio Tech International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/23/19
09/23
12:45
09/23/19
12:45
General news
Breaking General news story  »

St. Louis Federal Reserve…

IPHI

Inphi

$61.21

-2.28 (-3.59%)

12:43
09/23/19
09/23
12:43
09/23/19
12:43
Recommendations
Inphi analyst commentary  »

Inphi mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:41
09/23/19
09/23
12:41
09/23/19
12:41
Earnings
Trio-Tech reports Q4 EPS 12c vs. 17c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$377.77

-1.56 (-0.41%)

, ERJ

Embraer

$18.27

-0.46 (-2.46%)

12:37
09/23/19
09/23
12:37
09/23/19
12:37
Periodicals
Boeing bid of Embraer unit faces EU antitrust probe, Reuters reports »

The European Union's…

BA

Boeing

$377.77

-1.56 (-0.41%)

ERJ

Embraer

$18.27

-0.46 (-2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

OBAS

Optibase

$12.50

(0.00%)

12:36
09/23/19
09/23
12:36
09/23/19
12:36
Hot Stocks
Optibase: Appeal filed against court decision to deny motion to approve claim »

Optibase announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$114.56

-1.6 (-1.38%)

12:35
09/23/19
09/23
12:35
09/23/19
12:35
Options
Eli Lilly put volume heavy and directionally bearish »

Bearish flow noted in Eli…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 23

    Oct

AEM

Agnico Eagle

$59.23

1.02 (1.75%)

12:32
09/23/19
09/23
12:32
09/23/19
12:32
Conference/Events
Agnico Eagle management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 24

    Oct

TRT

Trio-Tech

$3.79

0.08 (2.16%)

12:26
09/23/19
09/23
12:26
09/23/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Trio-Tech »

Trio Tech International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$5.65

0.38 (7.21%)

12:25
09/23/19
09/23
12:25
09/23/19
12:25
Options
Coeur Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
09/23/19
09/23
12:20
09/23/19
12:20
General news
A Firming Pattern for U.S. Producer Sentiment: »

A Firming Pattern for…

PSTV

Plus Therapeutics

$11.00

3.04 (38.19%)

12:17
09/23/19
09/23
12:17
09/23/19
12:17
Syndicate
Plus Therapeutics 3M unit offering priced at $5 per unit »

Plus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/23/19
09/23
12:17
09/23/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/23/19
09/23
12:16
09/23/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYSI

BeyondSpring

$18.78

0.92 (5.15%)

12:15
09/23/19
09/23
12:15
09/23/19
12:15
Hot Stocks
BeyondSpring to present Pegfilgrastim data at ESMO Congress »

BeyondSpring announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

AZO

AutoZone

$1,160.25

-0.13 (-0.01%)

, KMX

CarMax

$86.63

1.95 (2.30%)

12:15
09/23/19
09/23
12:15
09/23/19
12:15
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$1,160.25

-0.13 (-0.01%)

KMX

CarMax

$86.63

1.95 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.